• Aclara BioSciences Inc., of Mountain View, Calif., formed its scientific advisory board, consisting of David Agus, Carlos Arteaga, P.J. Utz and Owen Witte.

• Active Pass Pharmaceuticals, of Vancouver, British Columbia, added Leslie Benet, Geoffrey Change and Alan Verkman to its scientific advisory board.

• Advanced Biotherapy Inc., of Los Angeles, said Joseph Bellanti rejoined its board.

• Anadys Pharmaceuticals Inc., of San Diego, appointed George Scangos to its board.

• Applied DNA Sciences Inc., of Los Angeles, appointed Julia Hunter vice president and director.

• AVI BioPharma Inc., of Portland, Ore., appointed Janet Rose Christensen vice president, regulatory affairs and quality.

• Callisto Pharmaceuticals Inc., of New York, added Moshe Talpaz to its scientific advisory board.

• Coratus Genetics Inc., of Atlanta, appointed Nina Vincent Sewell senior vice president, clinical regulatory. It also named Yawen Chiang senior vice president, chief scientific officer; Jack Callicutt vice president, finance and administration; and Robert Atwood executive vice president.

• DOV Pharmaceuticals Inc., of Hackensack, N.J., appointed Warren Stern senior vice president, drug development.

• EntreMed Inc., of Rockville, Md., appointed Dwight Bush to its board.

• Flagship Ventures in Cambridge, Mass., added Patrick Gage as venture partner to focus on drug discovery and drug development ventures.

• Genaera Corp., of Plymouth Meeting, Pa., added John Skolas as senior vice president, chief financial officer, general counsel and secretary.

• Hemispherx Biopharma Inc., of Philadelphia, appointed Jack Gwaltney and James Rahal to its scientific advisory board.

• Inovio AS, of Oslo, Norway, appointed David Pyrce chief business officer.

• Inpharmatica Ltd., of London, appointed Edwin Moses nonexecutive chairman.

• Invitrogen Corp., of Carlsbad, Calif., appointed Benjamin Bulkley senior vice president of commercial operations and promoted John Thompson to senior vice president of corporate development.